Intelligent Bio Solutions (INBS) investor relations material

Product and value proposition

• Intelligent Fingerprinting uses fingertip sweat to screen for recent use of opiates, cocaine, methamphetamine and cannabis; the portable system is designed for fast, hygienic, cost-effective testing.

• Donors press fingertips on the collection area for 5 seconds; results are available in less than 10 minutes, with a validation study underway for a rapid cartridge targeting 70% faster results.

• The detection window is up to 16–24 hours, focusing on recent use and potential fitness for duty rather than historical use.

• Testing comparison cites average annual costs of $5,500 for fingerprint, ~$7,600 for saliva and ~$7,750 for urine, based on 80 tests per year and stated cost assumptions.

Commercial traction and financial performance

• 1,886 readers installed and 502 active customers as of June 30, 2026; customer accounts span 35 countries and territories.

• FY2026 revenue was $4.21M versus $3.05M in FY2025; gross margin was 48.6% versus 40.8%.

• The model combines reader sales with recurring disposable cartridge sales.

• Syrma Johari manufacturing partnership is expected to deliver >40% annual production cost savings and ~20 percentage point gross-margin improvement.

FDA progress and milestones

• A new 510(k) submission was filed September 9, 2026, seeking clearance for codeine detection; the prior FDA review required broader evidence.

• The submission’s multi-site method comparison study reported accuracy above 98%, sensitivity above 94% and 100% specificity across three U.S. clinical sites.

• If clearance is received in H1 2027, planned steps include establishing a distribution network and starting U.S. studies to expand indications; rapid cartridge completion is targeted for H2 2027.

• A 510(k) application for cannabis, cocaine and methamphetamine is targeted for H1 2028.